Alongside traditional self-reported assessments of pain intensity, functional disability, quality of life, depression, anxiety and stress, the trial incorporates objective physiological markers such as cortisol, β-endorphins, substance-P, IL-6, CRP and HRV. The gene discussed is TAC1; the disease is major depressive disorder.